Breaking News


Briakinumab is safe and efficacious in phase II and III trials in psoriasis


Data from two clinical studies of briakinumab (ABT-874; Abbott), a fully human monoclonal antibody designed to target and neutralize interleukin-12 (IL-12) and IL-23 for the treatment of patients with moderate to severe psoriasis, were recently presented at the Summer Meeting of the American Academy of Dermatology held in Chicago. A 12-week, randomized, double-blind, placebo-controlled, phase II trial evaluated the safety and efficacy of subcutaneous injections of briakinumab versus placebo in 180 subjects with psoriasis affecting > 10% of their body surface area and exhibiting a Psoriasis Area and Severity Index (PASI) score >= 12 ( Identifier NCT00292396). Briakinumab was administered at five treatment schedules: a single 200-mg dose at week 0, 100 mg ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list